IsoTis raises $5 million in private placement:
This article was originally published in Clinica
IsoTis, a privately-owned Dutch company researching bioimplant coating technology and tissue engineering, has raised Fl10 million ($5 million) from its shareholders in a private placement. The money - from investors such as Atlas Ventures, GIMV and 3i - will enable the company, based in Bilthoven, to enlarge its R&D and clean room facilities.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.